ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1303 • ACR Convergence 2023

    Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis

    Audrey-Anne Couture1, Nathalie Carrier2, Hugues Allard-Chamard3, Sophie ROUX3, Patrick Liang3 and Gilles Boire3, 1University of Montréal, Montréal, QC, Canada, 2CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, 3Université de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
  • Abstract Number: 1319 • ACR Convergence 2023

    Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients

    Belén Atienza-Mateo1, Ana Serrano-Combarro2, Maria Martin-Lopez3, Santos Castañeda4, Rafael Benito Melero-Gonzalez5, Jesus Loarce-Martos6, Natalia Mena Vazquez7, Carmen carrasco-Cubero8, Carolina Diez-Morrondo9, David Castro-Corredor10, Tomás Vazquez-Rodriguez11, andrea Garcia-Valle12, Gema Bonilla13, Marina Rodriguez-lopez14, Ignacio Brana Abascal15, SARA MARIA ROJAS HERRERA16, Juan Camilo Sarmiento-Monroy17, Pablo Andujar-Brazal18, Juan Ramon De Dios19, Carmen Gonzalez-Montagut Gomez20, Sergio Ordonez-Palau21, Anahy Maria Brandy-Garcia22, Fernando Lozano23, Maria Lopez-Lasanta24, Cristina Campos Fernández25, Marta Garijo Bufort26, Ivette Casafont-Sole27, Calderon Goercke28, Carlota Laura Iñiguez29, Francisco Ortiz-Sanjuán30, Emilio Giner-Serret31, Bryan Josue Flores Robles32, Mireia Moreno33, Evelin Cecilia Cervantes-Perez34, Diego Ferrer35, Ricardo Blanco36 and On behalf of the Collaborative Group Members37, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 3Hospital 12 de Octubre, Madrid, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5CHU Vigo, O Carballino, Spain, 6Ramón y Cajal University Hospital, Madrid, Spain, 7IBIMA, Málaga, Spain, 8Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, 9Division of Rheumatology, Hospital de León, León, Spain, 10General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, 11Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, 12Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, 13Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 14Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, 15Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 16Division of Rheumatology, Hospital de Mérida, Mérida, Spain, 17Hospital Clínic, Barcelona, Spain, 18Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, 19Hospital Universitario Araba, Vitoria, Spain, 20H. Clínico Universitario de Valladolid, Valladolid, Spain, 21H. Arnau de Vilanova, Lleida, Spain, 22Hospital Germans Trias i Pujol, Badalona, Spain, 23Hospital Universitario 12 de Octubre, Madrid, Spain, 24Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, 25Hospital General Universitario Valencia, Valencia, Spain, 26H. de Sagunto, Valencia, Italy, 27Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 28Hospital Universitario Marqués de Valdecilla, Santander, Spain, 29Hospital Universitario Lucus Augusti, Lugo, Spain, 30Hospital Universitario y Politécnico La Fe, Valencia, Spain, 31Hospital Royo Villanova, Teruel, Spain, 32Hospital Universitario San Pedro, Logroño, Spain, 33Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 34Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 35Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 36Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 37Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…
  • Abstract Number: 1336 • ACR Convergence 2023

    Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering

    Zohra Layegh1, Femke Hooijberg2, Floris loeff3, lisanne Dijk3, Gaelle vaz3, Theo Rispens3, radboud J.e.m. Dolhain4, Gertjan Wolbink5 and Pascal de Jong1, 1Erasmus medical center, Rotterdam, Netherlands, 2Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, 3Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands, 5Reade, Amsterdam, Netherlands

    Background/Purpose: Due to the improved management strategies and availability of biologic disease-modifying antirheumatic drugs (bDMARDs), ~60% of the rheumatoid arthritis (RA) patients will achieve sustained…
  • Abstract Number: 1582 • ACR Convergence 2023

    Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

    Bryant England1, Joshua Baker2, Michael George2, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Harlan Sayles1, Fang Yu1, Jorge Rojas Jr3, Brian Sauer4, Grant Cannon5, Jeffrey R Curtis6 and Ted R Mikuls7, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
  • Abstract Number: 1717 • ACR Convergence 2023

    Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis

    Nathalie Burg1, Miles Tran2, Kevin Wei3, Carl Blobel1 and Jane Salmon1, 1Hospital for Special Surgery, New York, NY, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (EC), but the contribution of ECs to inflammatory arthritis…
  • Abstract Number: 1737 • ACR Convergence 2023

    ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA

    Veerle Derksen1, Klara Martinsson2, René Toes1, Daniel Sjöberg3, Thomas Huizinga1, Alf Kastbom4, Anna Svärd3 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Linköping University, Linköping, Sweden, 3Centre for Clinical Research Dalarna, Uppsala, Sweden, 4Linköping University, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
  • Abstract Number: 1753 • ACR Convergence 2023

    Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint

    Georgios Vasileiadis1, Anna-Karin Hultgård Ekwall2, Reshmi Sureshkumar1, Monica Guma3, Anna Rudin4, Yuan Zhang1 and Cristina Maglio1, 1Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3San Diego VA Healthcare Service, La Jolla, CA, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Several metabolic pathways have been implicated in rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) aggressive phenotype1,2. Here, we aimed to analyse the full spectrum of…
  • Abstract Number: 1769 • ACR Convergence 2023

    TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model

    Margaret Chang1, Maryrose Hahn2, Madison Mangin1, Brian Wauford1, Rachel Blaustein3, Lauren Henderson1, Kevin Wei4 and Peter Nigrovic1, 1Boston Children's Hospital, Boston, MA, 2Division of Immunology, Boston Children's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are chronic autoimmune diseases that tend to flare repeatedly in the same joints, displaying joint-specific memory.…
  • Abstract Number: 1868 • ACR Convergence 2023

    Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial

    Signe Møller-Bisgaard1, Kim Hørslev-Petersen2, Lykke Ørnbjerg1, Bo Ejbjerg3, Merete L Hetland1, Jakob Moeller4, Robin Christensen5, Sabrina Mai Nielsen6, Daniel Glinatsi7, Mikael Boesen8, Kristian Stengaard-Pedersen9, Ole Rintek Madsen10, Bente Jensen11, Jan Alexander Villadsen2, Ellen-Margrethe Hauge9, Oliver Hendricks2, Hanne Merete Lindegaard12, Niels Steen Krogh13, Anne Grethe Jurik9, Henrik Thomsen4 and Mikkel Østergaard14, 1Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 2Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 3Slagelse Hospital, Slagelse, Denmark, 4Herlev-Gentofte Hospital, Herlev, Denmark, 5Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 6The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 7Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, 8Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, 9Aarhus University Hospital, Aarhus, Denmark, 10Herlev-Gentofte Hospital, Gentofte, Denmark, 11Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 12Odense Hospital, Odense, Denmark, 13ZiteLab ApS, Frederiksberg, Denmark, 14Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Radiographic joint damage progresses in 20-30% of rheumatoid arthritis (RA) patients despite fulfilling clinical remission criteria (1). Osteitis assessed on MRI is a well…
  • Abstract Number: 2026 • ACR Convergence 2023

    Developing a Guided Joint Self-Exam for Rheumatoid Arthritis Patients to Use in Telehealth-Delivered Care

    Kelly Gavigan1, David Curtis2, Jeffrey Curtis3, W. Benjamin Nowell4, Danielle Ali5, Neelkamal Soares6, John Cush7, Rebecca Grainger8, Manas Jinka9, Sandeep Sodhi10, Natalie Fortune9 and Swamy Venuturupalli9, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Upper Nayack, NY, 6Western Mich Univ Homer Stryker MD Sch of Medicine, Kalamazoo, MI, 7University of Texas Southwestern Medical School, Dallas, TX, 8University of Otago, Wellington, New Zealand, 9Attune Health, Beverly Hills, CA, 10Illumination Health, Hoover, AL

    Background/Purpose: Telehealth services and, increasingly, remote therapeutic monitoring, can be used to enable the continuum of clinical care in out-of-office settings. This remotely provided care…
  • Abstract Number: 2107 • ACR Convergence 2023

    Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study

    Nicholas Wiemer1, Yue Yin2 and Tarun Sharma1, 1Allegheny Health Network, Pittsburgh, PA, 2Allegheny Health Network Singer Research Institute, Pittsburgh, PA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and potentially debilitating disease.Social determinants, including smoking and depression, have been shown to be linked to worse clinical…
  • Abstract Number: 2123 • ACR Convergence 2023

    Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?

    Jia-Feng Chen1, Tien-Tsai Cheng2 and Hong-Yo Kang3, 1Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 2Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, 3Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan

    Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
  • Abstract Number: 2139 • ACR Convergence 2023

    Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort

    Namrata Singh1, Aaron Baraff2, K Wysham3, Punyasha Roul4, Grant Cannon5, Brian Sauer6, Geoffrey Thiele4, Bryant England4, Ted R Mikuls7 and Joshua Baker8, 1University of Washington, Bellevue, WA, 2VA Puget Sound Seattle, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Nebraska Medical Center, Omaha, NE, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
  • Abstract Number: 2155 • ACR Convergence 2023

    The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies

    Peter C. Taylor1, Arthur Kavanaugh2, Peter Nash3, Janet Pope4, Georg Pongratz5, Bruno Fautrel6, Rieke Alten7, Ken Hasegawa8, Shangbang Rao9, Dick de Vries10, Pieter-Jan Stiers11, Chris Watson12 and René Westhovens13, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 3School of Medicine, Griffith University, Brisbane, Australia, 4University of Western Ontario, London, ON, Canada, 5Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, 6Sorbonne Université APHP, Paris, France, 7Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 8Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, 9Biostatistics, Gilead Sciences, Inc., Foster City, CA, 10Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, 11Biostatistics, Galapagos NV, Mechelen, Belgium, 12Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 13Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
  • Abstract Number: 2172 • ACR Convergence 2023

    Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, libe Ibarrola-Paino3, Ivette Casafont-Sole4, Rafael Benito Melero-Gonzalez5, Alba Perez Linaza6, Santos Castañeda7, Rafaela Ortega Castro8, Natalia Mena Vazquez9, Nuria Vegas Revenga10, Lucia Cristina Dominguez Casas11, Elena Cañadillas-Sanchez12, Miriam Retuerto-Guerrero13, Lorena Perez-Albadalejo14, Ruben Lopez-Sanchez15, MARIA GUADALUPE MANZANO CANABAL16, Anahy Maria Brandy-Garcia17, Patricia Lopez-Viejo18, Gema Bonilla19, Olga Maiz-Alonso20, Carmen carrasco-Cubero21, Marta Garijo Bufort22, Mireia Moreno23, Ana Urruticoechea24, Sergio Ordonez-Palau25, Carmen Gonzalez-Montagut Gomez26, andrea Garcia-Valle27, Marta López28, Fernando Lozano29, Tomás Vazquez-Rodriguez30, Maria Martin-Lopez31, Juan Maria Blanco-Madrigal32, Cristina Arciniega33, Ignacio Brana Abascal34, Jesus Loarce-Martos35, Emilio Giner-Serret36, Virginia Ruiz-Esquide37, Clara ventin-Rodriguez38, Marina Rodriguez-lopez39, Pablo Andujar-Brazal40, Julia Fernandez-Melon41, Lilian Maria Lopez42, Antonio Juan Mas43, carlos Fernandez-Diaz44, Javier Loricera45, Diego Ferrer46 and Ricardo Blanco47, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Universitario de Navarra, Pamplona, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5CHU Vigo, O Carballino, Spain, 6SERV. REUMATOLOGIA, Cadiz, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Hospital Reina Sofía, Cordoba, Spain, 9IBIMA, Málaga, Spain, 10Hospital Galdakao- Usansolo, Galdakao, Spain, 11Hospital Universtario San Agustin, Oviedo, Spain, 12Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 13Rheumatology, Hospital Universitario de León, León, Spain, 14Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, 15Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, 16CAZA, Salamanca, Spain, 17Hospital Germans Trias i Pujol, Badalona, Spain, 18Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, 19Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 20University Hospital Donostia, San Sebastian, Spain, 21Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, 22Hospital de Sagunto, Valencia, Spain, 23Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 24Hospital Can Misses, Ibiza, Spain, 25H. Arnau de Vilanova, Lleida, Spain, 26H. Clínico Universitario de Valladolid, Valladolid, Spain, 27Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, 28Hospital Universitario Arava, Pamplona, Spain, 29Hospital Universitario 12 de Octubre, Madrid, Spain, 30Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, 31Hospital 12 de Octubre, Madrid, Spain, 32Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, 33Hospital de Mérida, Mérida, Spain, 34Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 35Ramón y Cajal University Hospital, Madrid, Spain, 36Hospital Royo Villanova, Teruel, Spain, 37Hospital Clinic, Rheumatology, Barcelona, Spain, 38Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, 39Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, 40Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, 41Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 42Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, 43Son Llazter University Hospital, Palma, Spain, 44Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, 45Hospital Universitario Marqués de Valdecilla, Santander, Spain, 46Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 47Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown…
  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology